NEURONES: 8.6% organic growth in 2024

12.02.25 17:40 Uhr

Werte in diesem Artikel
Aktien

47,60 EUR 0,90 EUR 1,93%

PRESS INFORMATION
Heading: 2024 annual revenues        Nanterre, February 12, 2025 (after trading)

Wer­bung

8.6% organic growth in 2024

(being audited, in € millions)20232024Growthof which organic
Revenues741.2810.4+ 9.3%+ 8.6%

Achievements

Forecasts for the year were exceeded, both in terms of activity and operating profit:

Wer­bung

  • revenues totaled €810.4 million, up 9.3% (with 8.1% growth in Q4 );

  • operating profit represented 9.6% of revenues (€77.9 million *).

With double-digit growth, the Group's expansion is driven by digital projects, data, cybersecurity, public clouds, sovereign ans trusted clouds (SecNumCloud).

The Group’s net increase in the payroll of 340 by 2024 has been supplemented by greater use of subcontracting.

Wer­bung

The full final annual results will be published on Wednesday, March 5, 2025 after the stock exchange closes.

Outlook

As usual, the forecasts for 2025 will be posted along with the Group's Q1 revenues.

* being audited.

About NEURONES
With 7,100 experts, and ranking among the French leaders in consulting and digital services, NEURONES helps large companies and organizations implement their digital projects, transform their IT infrastructures and adopt new uses.

Euronext Paris (compartment B - NRO) – Euronext Tech Leaders – DSS mid-caps – ‘PEA-PME’ eligible
www.neurones.net

Press Relations:
O'Connection
Julia Philippe-Brutin
Tel.: +33 (0)6 03 63 06 03

jpbrutin@oconnection.fr


NEURONES
Matthieu Vautier
Tel.: +33 (0)1 41 37 41 37
rp@neurones.net
Investor Relations:
NEURONES
Paul-César Bonnel
Tel.: +33 (0)1 41 37 41 37
investisseurs@neurones.net

Attachment


Ausgewählte Hebelprodukte auf NeuronesAct.

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf NeuronesAct.

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu NeuronesAct.

Wer­bung